IP Library › Granted Patent US 12,662,544
Granted Patent B2
US 12,662,544 · App. 18/399,071 · Granted Jun 23, 2026

Antagonistic anti-tumor necrosis factor receptor 2 antibodies

Inventor: Denise L. Faustman (Boston, MA)
Assignee: The General Hospital Corporation
C07K16/2878A61K39/001117A61P31/18A61P35/00C07K2317/34C07K2317/54C07K2317/565C07K2317/622C07K2317/73C07K2317/76C07K2317/92Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,662,544
App. No.
18/399,071
Filed
Dec 28, 2023
Granted
Jun 23, 2026
Kind
B2
Art Unit
1674
USPC
424/85.7
Abstract

The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

Claims (42)

1 . A method of slowing progression of a cancer in a human that is undergoing treatment with an anti-cancer agent, said method comprising administering to the human an antibody or antigen-binding fragment thereof capable of specifically binding human tumor necrosis factor receptor 2 (TNFR2), wherein the antibody or antigen-binding fragment thereof comprises the following complementarity determining regions (CDRs):

(a) a CDR-heavy chain 1 (CDR-H1) having the amino acid sequence GYTFTDYX (SEQ ID NO: 257);

(b) a CDR-H2 having the amino acid sequence VDPEYGST (SEQ ID NO: 258);

(c) a CDR-H3 having the amino acid sequence ARDDGSYSPFDYWG (SEQ ID NO: 259);

(d) a CDR-light chain 1 (CDR-L1) having the amino acid sequence QNINKY (SEQ ID NO: 260);

(e) a CDR-L2 having the amino acid sequence TYS or YTS; and

(f) a CDR-L3 having the amino acid sequence CLQYVNLXT (SEQ ID NO: 261), and

wherein each X is independently leucine or isoleucine.

2 . The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is a human antibody or antigen-binding fragment thereof, a humanized antibody or antigen-binding fragment thereof, or a chimeric antibody or antigen-binding fragment thereof.

3 . The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of a monoclonal antibody or antigen-binding fragment thereof, a polyclonal antibody or antigen-binding fragment thereof, an Fab, a bispecific antibody or antigen-binding fragment thereof, a monovalent antibody or antigen-binding fragment thereof, a single-chain Fv molecule, a bispecific single chain Fv ((scFv′) 2) molecule, a domain antibody, a diabody, a triabody, a SMIP, a Fv fragment, a Fab fragment, a F(ab′) 2 molecule, and a tandem scFv (taFv) fragment.

4 . The method of claim 1 , wherein the cancer is selected from the group consisting of acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related lymphoma, anal cancer, astrocytoma, bile duct cancer, bladder cancer, osteosarcoma, malignant fibrous histiocytoma, brain stem glioma, visual pathway and hypothalamic glioma, bronchial adenomas/carcinoids, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, clear cell sarcoma of tendon sheaths, colon cancer, colorectal cancer, T-cell lymphoma, epithelial cancer, Ewing's family of tumors, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, hairy cell leukemia, Hodgkin's lymphoma, hypopharyngeal cancer, Kaposi's sarcoma, laryngeal cancer, pituitary cancer, plasma cell neoplasm/multiple myeloma, pleuropulmonary blastoma, small cell lung cancer, small intestine cancer, squamous neck cancer, testicular cancer, thyroid cancer, urethral cancer, uterine sarcoma, and vaginal cancer.

5 . The method of claim 1 , wherein the cancer is selected from the group consisting of breast cancer, endometrial cancer, esophageal cancer, gastric cancer, hepatocellular cancer, kidney cancer, multiple myeloma, skin cancer, lung cancer, ovarian cancer, brain cancer, lymphoid cancer, pharyngeal cancer, and prostate cancer.

6 . The method of claim 1 , wherein the cancer is selected from the group consisting of ocular cancer, bone cancer, head and neck cancer, and soft tissue sarcoma.

7 . The method of claim 1 , wherein the CDR-H1 has the amino acid sequence GYTFTDYL (SEQ ID NO: 274) or GYTFTDYI (SEQ ID NO: 275), and/or the CDR-L2 has the amino acid sequence YTS.

8 . The method of claim 1 , wherein the CDR-H1 has the amino acid sequence GYTFTDYL (SEQ ID NO: 274), the CDR-L2 has the amino acid sequence YTS, the CDR-L3 has the amino acid sequence CLQYVNLIT (SEQ ID NO: 273).

9 . The method of claim 1 , wherein the antibody or antigen-binding fragment thereof further comprises a framework region comprising:

(a) the amino acid sequence LLIR (SEQ ID NO: 262) bound to the N-terminus of the CDR-L2; and/or

(b) the amino acid sequence TLE bound to the C-terminus of the CDR-L2.

10 . The method of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a non-native constant region.

11 . The method of claim 10 , wherein the non-native constant region is a human constant region.

12 . The method of claim 1 , wherein the antibody or antigen-binding fragment thereof lacks all or a portion of an Fc domain.

13 . The method of claim 1 , wherein the antibody or antigen-binding fragment thereof is conjugated to an additional therapeutic agent.

14 . The method of claim 1 , wherein the anti-cancer agent is an immunotherapy agent.

15 . The method of claim 14 , wherein the immunotherapy agent is an anti-CTLA-4 antibody or antigen-binding fragment thereof, an anti-PD-1 antibody or antigen-binding fragment thereof, an anti-PD-L1 antibody or antigen-binding fragment thereof, an anti-PD-L2 antibody or antigen-binding fragment thereof, a TNF-α cross-linking antibody or antigen-binding fragment thereof, a TRAIL cross-linking antibody or antigen-binding fragment thereof, an anti-CD27 antibody or antigen-binding fragment thereof, an anti-CD30 antibody or antigen-binding fragment thereof, an anti-CD40 antibody or antigen-binding fragment thereof, an anti-4-1BB antibody or antigen-binding fragment thereof, an anti-GITR antibody or antigen-binding fragment thereof, an anti-OX40 antibody or antigen-binding fragment thereof, an anti-TRAILR1 antibody or antigen-binding fragment thereof, an anti-TRAILR2 antibody or antigen-binding fragment thereof, or an anti-TWEAKR antibody or antigen-binding fragment thereof.

16 . The method of claim 8 , wherein the antibody or antigen-binding fragment thereof is conjugated to an additional therapeutic agent.

17 . The method of claim 8 , wherein the anti-cancer agent is an immunotherapy agent.

18 . The method of claim 17 , wherein the immunotherapy agent is an anti-CTLA-4 antibody or antigen-binding fragment thereof, an anti-PD-1 antibody or antigen-binding fragment thereof, an anti-PD-L1 antibody or antigen-binding fragment thereof, an anti-PD-L2 antibody or antigen-binding fragment thereof, a TNF-α cross-linking antibody or antigen-binding fragment thereof, a TRAIL cross-linking antibody or antigen-binding fragment thereof, an anti-CD27 antibody or antigen-binding fragment thereof, an anti-CD30 antibody or antigen-binding fragment thereof, an anti-CD40 antibody or antigen-binding fragment thereof, an anti-4-1BB antibody or antigen-binding fragment thereof, an anti-GITR antibody or antigen-binding fragment thereof, an anti-OX40 antibody or antigen-binding fragment thereof, an anti-TRAILR1 antibody or antigen-binding fragment thereof, an anti-TRAILR2 antibody or antigen-binding fragment thereof, or an anti-TWEAKR antibody or antigen-binding fragment thereof.

19 . A method of slowing progression of a cancer in a human comprising administering to the human a combination comprising an antibody or antigen-binding fragment thereof capable of specifically binding human TNFR2 and an additional immunotherapy agent, wherein the antibody or antigen-binding fragment thereof comprises the following CDRs:

(a) a CDR-H1 having the amino acid sequence GYTFTDYX (SEQ ID NO: 257);

(b) a CDR-H2 having the amino acid sequence VDPEYGST (SEQ ID NO: 258);

(c) a CDR-H3 having the amino acid sequence ARDDGSYSPFDYWG (SEQ ID NO: 259);

(d) a CDR-L1 having the amino acid sequence QNINKY (SEQ ID NO: 260);

(e) a CDR-L2 having the amino acid sequence TYS or YTS; and

(f) a CDR-L3 having the amino acid sequence CLQYVNLXT (SEQ ID NO: 261),

and wherein each X is independently leucine or isoleucine.

20 . The method of claim 19 , wherein the CDR-H1 has the amino acid sequence GYTFTDYL (SEQ ID NO: 274), the CDR-L2 has the amino acid sequence YTS, the CDR-L3 has the amino acid sequence CLQYVNLIT (SEQ ID NO: 273).

21 . The method of claim 19 , wherein the method comprises administering the antibody or antigen-binding fragment thereof and to the human prior to or after the additional immunotherapy agent.

22 . The method of claim 21 , wherein the method comprises administering the antibody or antigen-binding fragment thereof to the human prior to the additional immunotherapy agent.

23 . The method of claim 21 , wherein the method comprises administering the antibody or antigen-binding fragment thereof to the human after the additional immunotherapy agent.

24 . The method of claim 19 , wherein the method comprises simultaneously administering the antibody or antigen-binding fragment thereof and the additional immunotherapy agent to the human.

25 . The method of claim 20 , wherein the antibody or antigen-binding fragment thereof is conjugated to an additional therapeutic agent.

26 . The method of claim 20 , wherein the additional immunotherapy agent is an anti-CTLA-4 antibody or antigen-binding fragment thereof, an anti-PD-1 antibody or antigen-binding fragment thereof, an anti-PD-L1 antibody or antigen-binding fragment thereof, an anti-PD-L2 antibody or antigen-binding fragment thereof, a TNF-α cross-linking antibody or antigen-binding fragment thereof, a TRAIL cross-linking antibody or antigen-binding fragment thereof, an anti-CD27 antibody or antigen-binding fragment thereof, an anti-CD30 antibody or antigen-binding fragment thereof, an anti-CD40 antibody or antigen-binding fragment thereof, an anti-4-1BB antibody or antigen-binding fragment thereof, an anti-GITR antibody or antigen-binding fragment thereof, an anti-OX40 antibody or antigen-binding fragment thereof, an anti-TRAILR1 antibody or antigen-binding fragment thereof, an anti-TRAILR2 antibody or antigen-binding fragment thereof, or an anti-TWEAKR antibody or antigen-binding fragment thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2024
From: FAUSTMAN, DENISE L.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 066901/0137 →
Continuity (4)
Continuation 16099632
Provisional Application 62457496 · Feb 10, 2017
Provisional Application 62336468 · May 13, 2016
Related Publication 20240270860A1 · Aug 15, 2024
References Cited (400)
US 4309418A · Green · 1982 [cited by applicant]
US 4457916A · Hayashi et al. · 1984 [cited by applicant]
US 4495282A · Ohnishi et al. · 1985 [cited by applicant]
US 4677063A · Mark et al. · 1987 [cited by applicant]
US 4677064A · Mark et al. · 1987 [cited by applicant]
US 4681760A · Fathman · 1987 [cited by applicant]
US 4791101A · Adolf · 1988 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4879226A · Wallace et al. · 1989 [cited by applicant]
US 4963354A · Shepard et al. · 1990 [cited by applicant]
US 4985241A · Zimmerman et al. · 1991 [cited by applicant]
US 5002876A · Sreekrishna et al. · 1991 [cited by applicant]
US 5059530A · Oshima et al. · 1991 [cited by applicant]
US 5139481A · Faustman et al. · 1992 [cited by applicant]
US 5215743A · Singh et al. · 1993 [cited by applicant]
US 5283058A · Faustman · 1994 [cited by applicant]
US 5288852A · Yamada et al. · 1994 [cited by applicant]
US 5370870A · Wong · 1994 [cited by applicant]
US 5487984A · Allet et al. · 1996 [cited by applicant]
US 5538854A · Faustman · 1996 [cited by applicant]
US 5560908A · Satoh et al. · 1996 [cited by applicant]
US 5593698A · Weiner et al. · 1997 [cited by applicant]
US 5677425A · Bodmer et al. · 1997 [cited by applicant]
US 5783216A · Faustman · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5843425A · Sachs et al. · 1998 [cited by applicant]
US 5843452A · Wiedmann et al. · 1998 [cited by applicant]
US 5874306A · Beattie et al. · 1999 [cited by applicant]
US 5919452A · Le et al. · 1999 [cited by applicant]
US 5939532A · Nakamura et al. · 1999 [cited by applicant]
US 6046031A · Ni et al. · 2000 [cited by applicant]
US 6056952A · Rosenberg · 2000 [cited by applicant]
US 6159461A · Besmer et al. · 2000 [cited by applicant]
US 6165737A · Wang et al. · 2000 [cited by applicant]
US 6177076B1 · Lattime et al. · 2001 [cited by applicant]
US 6284879B1 · Faustman · 2001 [cited by applicant]
US 6414218B1 · Faustman et al. · 2002 [cited by applicant]
US 6420139B1 · Classen · 2002 [cited by applicant]
US 6491908B1 · Rosenberg · 2002 [cited by applicant]
US 6599710B1 · Faustman · 2003 [cited by applicant]
US 6617171B2 · Faustman et al. · 2003 [cited by applicant]
US 6660487B2 · Faustman · 2003 [cited by applicant]
US 6709833B2 · Fukui et al. · 2004 [cited by applicant]
US 6773705B1 · Faustman et al. · 2004 [cited by applicant]
US 6844011B1 · Faustman · 2005 [cited by applicant]
US 6866843B2 · Habener et al. · 2005 [cited by applicant]
US 6923959B2 · Habener et al. · 2005 [cited by applicant]
US 6984380B1 · Faustman · 2006 [cited by applicant]
US 7015037B1 · Furcht et al. · 2006 [cited by applicant]
US 7438902B2 · Habener et al. · 2008 [cited by applicant]
US 7485293B1 · Faustman · 2009 [cited by applicant]
US 7510877B2 · Yilmaz et al. · 2009 [cited by applicant]
US 7537756B2 · Habener et al. · 2009 [cited by applicant]
US 7582313B2 · Faustman · 2009 [cited by applicant]
US 7628988B2 · Faustman · 2009 [cited by applicant]
US 8017392B2 · Faustman · 2011 [cited by applicant]
US 8021693B2 · Faustman · 2011 [cited by applicant]
US 8173129B2 · Faustman · 2012 [cited by applicant]
US 8314213B2 · Bernett et al. · 2012 [cited by applicant]
US 8697077B2 · Faustman · 2014 [cited by applicant]
US 9522181B2 · Faustman · 2016 [cited by applicant]
US 9676862B2 · Ellmark et al. · 2017 [cited by applicant]
US 9821010B2 · Faustman · 2017 [cited by applicant]
US 10765700B2 · Faustman · 2020 [cited by applicant]
US 10906982B2 · Faustman · 2021 [cited by applicant]
US 10988543B2 · Thompson · 2021 [cited by applicant]
US 11844814B2 · Faustman · 2023 [cited by applicant]
US 11859002B2 · Faustman · 2024 [cited by applicant]
US 12152082B2 · Faustman · 2024 [cited by applicant]
US 20020106689A1 · Faustman et al. · 2002 [cited by applicant]
US 20020123472A1 · Faustman · 2002 [cited by applicant]
US 20020187548A1 · Keller et al. · 2002 [cited by applicant]
US 20030005469A1 · Faustman et al. · 2003 [cited by applicant]
US 20030031657A1 · Habener et al. · 2003 [cited by applicant]
US 20040028658A1 · Faustman · 2004 [cited by applicant]
US 20040031066A9 · Faustman et al. · 2004 [cited by applicant]
US 20040229785A1 · Faustman · 2004 [cited by applicant]
US 20050043514A1 · Fukui et al. · 2005 [cited by applicant]
US 20050158288A1 · Faustman · 2005 [cited by applicant]
US 20050158302A1 · Faustman et al. · 2005 [cited by applicant]
US 20050244386A1 · Habener et al. · 2005 [cited by applicant]
US 20060062769A1 · Habener et al. · 2006 [cited by applicant]
US 20070116688A1 · Faustman · 2007 [cited by applicant]
US 20080102054A1 · Faustman · 2008 [cited by applicant]
US 20080175830A1 · Steinman et al. · 2008 [cited by applicant]
US 20080176796A1 · Bradley et al. · 2008 [cited by applicant]
US 20090028877A1 · Iida et al. · 2009 [cited by applicant]
US 20100068177A1 · Faustman · 2010 [cited by applicant]
US 20100298232A1 · Liu · 2010 [cited by applicant]
US 20110236374A1 · Shitara et al. · 2011 [cited by applicant]
US 20120066777A1 · Kawamura et al. · 2012 [cited by applicant]
US 20120115739A1 · Schmittling et al. · 2012 [cited by applicant]
US 20120196919A1 · Brown et al. · 2012 [cited by applicant]
US 20130064831A1 · Humphrey · 2013 [cited by applicant]
US 20140096274A1 · Quax et al. · 2014 [cited by applicant]
US 20140121123A1 · Wang et al. · 2014 [cited by applicant]
US 20150110794A1 · Sato et al. · 2015 [cited by applicant]
US 20150366909A1 · Faustman · 2015 [cited by applicant]
US 20170158771A1 · Glennie et al. · 2017 [cited by applicant]
US 20170226217A1 · Ellmark et al. · 2017 [cited by applicant]
US 20180044430A1 · Chiu et al. · 2018 [cited by applicant]
US 20190135929A1 · Faustman · 2019 [cited by applicant]
US 20190202925A1 · Thompson · 2019 [cited by applicant]
US 20200270355A1 · Faustman · 2020 [cited by applicant]
US 20210301028A1 · Thompson · 2021 [cited by applicant]
US 20210317221A1 · Faustman · 2021 [cited by applicant]
US 20210340268A1 · Faustman · 2021 [cited by applicant]
US 20220002423A1 · Faustman · 2022 [cited by applicant]
US 20220112299A1 · Faustman · 2022 [cited by applicant]
US 20230174659A1 · Faustman · 2023 [cited by applicant]
US 20230295326A1 · Faustman · 2023 [cited by applicant]
US 20230383003A1 · Faustman · 2023 [cited by applicant]
CN 101084014A · 2007 [cited by applicant]
CN 103249742A · 2013 [cited by applicant]
EP 0612529A2 · 1994 [cited by applicant]
EP 1707627A1 · 2006 [cited by applicant]
EP 2295588A1 · 2011 [cited by applicant]
JP 2010531138A · 2010 [cited by applicant]
JP 2013521311A · 2013 [cited by applicant]
KR 1020210061350A · 2021 [cited by applicant]
WO WO9204033A1 · 1992 [cited by applicant]
WO WO9302690A1 · 1993 [cited by applicant]
WO WO9409137A1 · 1994 [cited by applicant]
WO WO9524914A1 · 1995 [cited by applicant]
WO WO9525533A1 · 1995 [cited by applicant]
WO WO9708328A1 · 1997 [cited by applicant]
WO WO9713844A1 · 1997 [cited by applicant]
WO WO9721802A1 · 1997 [cited by applicant]
WO WO9953953A2 · 1999 [cited by applicant]
WO WO9959632A1 · 1999 [cited by applicant]
WO WO0053209A1 · 2000 [cited by applicant]
WO WO0144472A1 · 2001 [cited by applicant]
WO WO0191793A1 · 2001 [cited by applicant]
WO WO0226819A2 · 2002 [cited by applicant]
WO WO2004003164A2 · 2004 [cited by applicant]
WO WO2004022097A1 · 2004 [cited by applicant]
WO WO2005042727A2 · 2005 [cited by applicant]
WO WO2006038027A2 · 2006 [cited by applicant]
WO WO2006109044A2 · 2006 [cited by applicant]
WO WO2006119107A2 · 2006 [cited by applicant]
WO WO2008157394A2 · 2008 [cited by applicant]
WO WO2010124259A1 · 2010 [cited by applicant]
WO WO2011044368A1 · 2011 [cited by applicant]
WO WO2011107989A1 · 2011 [cited by applicant]
WO WO2011109789A2 · 2011 [cited by applicant]
WO WO2012122464A1 · 2012 [cited by applicant]
WO WO2014015101A1 · 2014 [cited by applicant]
WO WO2014124134A1 · 2014 [cited by applicant]
WO WO2015145360A1 · 2015 [cited by applicant]
WO WO2016032547A1 · 2016 [cited by applicant]
WO WO2016094309A1 · 2016 [cited by applicant]
WO WO2016187068A1 · 2016 [cited by applicant]
WO WO2017040312A1 · 2017 [cited by applicant]
WO WO2017083525A1 · 2017 [cited by applicant]
WO WO2017197331A2 · 2017 [cited by applicant]
WO WO2018064307A2 · 2018 [cited by applicant]
WO WO2018092907A1 · 2018 [cited by applicant]
WO WO2018115003A2 · 2018 [cited by applicant]
WO WO2019094559A2 · 2019 [cited by applicant]
WO WO2020041361A1 · 2020 [cited by applicant]
WO WO2020193718A1 · 2020 [cited by applicant]
Sasi et al., Breaking the ‘harmony’ of TNF-α signaling for cancer treatment, Oncogene, 31:4117-4127, 2012. [cited by examiner]
Allen et al., “Effect of bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes,” Diabetes Care. 22(10):1703-7 (1999). [cited by applicant]
Altomonte et al., “Serum levels of interleukin-1b, tumour necrosis factor-a and interleukin-2 in rheumatoid arthritis. Correlation with disease activity,” Clin Rheumatol. 11(2):202-205 (1992). [cited by applicant]
Anderson et al., “The NOD mouse: a model of immune dysregulation,” Annu Rev Immunol. 23:447-485 (2005). [cited by applicant]
Baeza et al., “Pancreatic regenerating gene overexpression in the nonobese diabetic mouse during active diabetogenesis,” Diabetes. 45(1):67-70 (1996) (5 pages). [cited by applicant]
Gage, “Mammalian neural stem cells,” Science. 287(5457):1433-1438 (2000). [cited by applicant]
Gage et al., “Multipotent progenitor cells in the adult dentate gyrus,” J Neurobiol. 36:249-266 (1998). [cited by applicant]
Ganoth et al., “A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation,” J Biol Chem. 263(25):12412-12419 (1988). [cited by applicant]
Gaur et al., “Induction of islet allotolerance in nonhuman primates,” Ann NY Acad Sci. 958:199-203 (2002). [cited by applicant]
Gazda et al., “Diabetes results from a late change in the autoimmune response of NOD mice,” J Autoimmun. 10(3):261-270 (1997). [cited by applicant]
Ghosh et al., “Activation in vitro of NF-kappaB by phosphorylation of its inhibitor IkappaB,” Nature. 344(6267):678-682 (1990). [cited by applicant]
Goldberg, “Functions of the proteasome: The lysis at the end of the tunnel,” Science. 268:522-523 (1995). [cited by applicant]
Goldberg, “The mechanism and functions of ATP-dependent proteases in bacterial and animal cells,” Eur J Biochem. 203:9-23 (1992). [cited by applicant]
Graves et al., “Lack of association between early childhood immunizations and beta-cell autoimmunity,” Diabetes Care. 22:1694-7 (1999). [cited by applicant]
Grewal et al., “Local expression of transgene encoded TNFalpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T Cells,” J Exp Med. 18… [cited by applicant]
Grilli et al., “Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation,” Science. 274:1383-1385 (1996). [cited by applicant]
Gronostajski et al., “The ATP dependence of the degradation of short- and long-lived proteins in growing fibroblasts,” J Biol Chem. 260(6):3344-3349 (1985). [cited by applicant]
Gueckel et al., “Mutations in the yeast proteasome beta-Type subunit Pre3 uncover position-dependent effects on proteasomal peptidase activity and in vivo function,” J Biol Chem. 273(31): 19443-19452 (1998). [cited by applicant]
Haas et al., “Pathways of ubiquitin conjugation,” FASEB J. 11:1257-1268 (1997). [cited by applicant]
Hartwell et al., “Aberrant cytokine regulation in macrophages from young autoimmune-prone mice: Evidence that the intrinsic defect in MRL macrophage IL-1 expression is transcriptionally controlled,” Mol Immunol. 32(10):… [cited by applicant]
Hayashi et al., “Essential role of human leukocyte antigen-encoded proteasome subunits in NF-kappaB activation and prevention of tumor necrosis factor-alpha-induced apoptosis,” J Biol Chem. 275(7):5238-5247 (2000). [cited by applicant]
Hayashi et al., “NOD mice are defective in proteasome production and activation of NF-kappaB,” Mol Cell Biol. 19(12):8646-8659 (1999). [cited by applicant]
Hershko et al., “The ubiquitin system for protein degradation,” Annu Rev Biochem. 61:761-807 (1992) (24 pages). [cited by applicant]
Hester et al., “Studies on the cytophilic properties of human beta2-microglobulin. II. The role of histocompatibility antigens,” Scand J Immunol. 9(2):125-134 (1979). [cited by applicant]
Hsu et al., “TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways,” Cell. 84:299-308 (1996). [cited by applicant]
Hyafil et al., “Dissociation and exchange of the beta2-microglobulin subunit of HLA-A and HLA-B antigens,” Proc Natl Acad Sci USA. 76(11):5834-5838 (1979). [cited by applicant]
Jackson et al., “Hematopoietic potential of stem cells isolated from murine skeletal muscle,” Proc Natl Acad Sci USA. 96(25):14482-14486 (1999) (6 pages). [cited by applicant]
Jacob et al., “Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development,” Int Immunol. 4(5):611-614 (1992). [cited by applicant]
Jakubowski et al., “Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer,” J Clin Oncol. 7(3):298-303 (1989). [cited by applicant]
Jiang et al., “Pluripotency of mesenchymal stem cells derived from adult marrow,” Nature. 418:41-49 (2002). [cited by applicant]
Juang et al., “Beneficial influence of glycemic control upon the growth and function of transplanted islets,” Diabetes. 43:1334-1339 (1994). [cited by applicant]
Kaufman et al., “Patterns of hemopoietic reconstitution in nonobese diabetic mice: dichotomy of allogeneic resistance versus competitive advantage of disease-resistant marrow,” J Immunol. 158(5):2435-2442 (1997). [cited by applicant]
Kopp et al., “Inhibition of NF-kappaB by sodium salicylate and aspirin,” Science. 265(5174):956-959 (1994). [cited by applicant]
Kuehnle et al., “The therapeutic potential of stem cells from adults,” BMJ. 325(7360):372-6 (2002). [cited by applicant]
Kwon et al., “Evidence for involvement of the proteasome complex (26S) and NFkappaB in IL-1beta-induced nitric oxide and prostaglandin production by rat islets and RINm5F Cells,” Diabetes. 47(4):583-591 (1998). [cited by applicant]
Kwon et al., “Interleukin-1beta-induced nitric oxide synthase expression by rat pancreatic beta-cells: Evidence for the involvement of nuclear factor kappaB in the signaling mechanism,” Endocrinology. 136(11):4790-4795 … [cited by applicant]
Laakko et al., “Versatility of merocyanine 540 for the flow cytometric detection of apoptosis in human and murine cells,” J Immunol Methods. 261(1-2):129-139 (2002). [cited by applicant]
Lanza et al., “Transplantation of encapsulated canine islets into spontaneously diabetic BB/Wor rats without immunosuppression,” Endocrinology. 131(2):637-642 (1992). [cited by applicant]
Lapchak et al., “Tumor necrosis factor production is deficient in diabetes-prone BB rats and can be corrected by complete Freund's adjuvant: A possible immunoregulatory role of tumor necrosis factor in the prevention of… [cited by applicant]
Lawrence et al., “Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions,” Nat Med. 7(4):383-385 (2001). [cited by applicant]
Lewis et al., “Integrins regulate the apoptotic response to DNA damage through modulation of p53,” Proc Natl Acad Sci USA. 99(6):3627-3632 (2002). [cited by applicant]
Macchi et al., “Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis,” NeuroReport. 10(25):399-402 (1999). [cited by applicant]
Mak et al., “Signaling for survival and apoptosis in the immune system,” Arthritis Res. 4(Suppl 3):S243-S252 (2002). [cited by applicant]
Markiewicz et al., “Long-term T cell memory requires the surface expression of self-peptide/major histocompatibility complex molecules,” Proc Natl Acad Sci USA. 95(6):3065-70 (1998). [cited by applicant]
Markmann et al., “Indefinite survival of MHC class I-deficient murine pancreatic islet allografts,” Transplantation. 54(6):1085-1089 (1992). [cited by applicant]
Matsumoto et al., “Liver organogenesis promoted by endothelial cells prior to vascular function,” Science. 294:559-563 (2001). [cited by applicant]
Mayer-Proschel et al., “Isolation of lineage-restricted neuronal precursors from multipotent neuroepithelial stem cells,” Neuron. 19:773-785 (1997). [cited by applicant]
McGuire et al., “An enzyme related to the high molecular weight multicatalytic proteinase, macropain, participates in a ubiquitin-mediated, ATP-stimulated proteolytic pathway in soluble extracts of BHK 21/C13 fibroblast… [cited by applicant]
McInerney et al., “Prevention of insulitis and diabetes onset by treatment with complete Freund's adjuvant in NOD mice,” Diabetes. 40:715-725 (1991). [cited by applicant]
Mercurio et al., “p105 and p98 precursor proteins play an active role in NF-Kappa B-mediated signal transduction,” Genes Dev. 7:705-718 (1993) (15 pages). [cited by applicant]
Mestas et al., “Of mice and not men: Differences between mouse and human immunology,” J Immunol. 172:2731-2738 (2004). [cited by applicant]
Mezey et al., “Turning blood into brain: Cells bearing neuronal antigens generated in vivo from bone marrow,” Science. 290: 1779-1782 (2000). [cited by applicant]
Miller et al., “Both the Lyt-2 [cited by applicant]
Mittelman et al., “A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion,” Invest New Drugs. 10(3):183-190 (1992). [cited by applicant]
Miyazaki et al., “Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic non-obese diabetic (NOD) mice: A longitudinal study,” Clin Exp Immunol. 60:622-630 (1985). [cited by applicant]
Morrison, “Stem cell potential: Can anything make anything?” Curr Biol. 11(1):R7-R9 (2001). [cited by applicant]
Nomikos et al., “Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice,” Diabetes. 35(11):1302-1304 (1986). [cited by applicant]
Offield et al., “PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum,” Development. 122(3):983-995 (1996). [cited by applicant]
Ono et al., “IDDM in BB rats. Enhanced MHC class I heavy-chain gene expression in pancreatic islets,” Diabetes. 37:1411-1418 (1988). [cited by applicant]
Orlowski, “The multicatalytic proteinase complex, a major extralysosomal proteolytic system,” Biochemistry. 29(45):10289-10297 (1990). [cited by applicant]
Osorio et al., “Beta-2 microglobulin gene disruption prolongs murine islet allograft survival in NOD mice,” Transplant Proc. 26(2):752 (1994). [cited by applicant]
Pestano et al., “Inactivation of misselected CD8 T cells by CD8 gene methylation and cell death,” Science. 284(5417):1187-91 (1999). [cited by applicant]
Petersen et al., “Bone marrow as a potential source of hepatic oval cells,” Science. 284(5417):1168-70 (1999). [cited by applicant]
Pozzilli, “BCG vaccine in insulin-dependent diabetes mellitus,” Lancet. 349(9064):1520-1 (1997). [cited by applicant]
Pontesilli et al., “Circulating lymphocyte populations and autoantibodies in non-obese diabetic (NOD) mice: a longitudinal study,” Clin Exp Immunol. 70(1):84-93 (1987). [cited by applicant]
Prieto et al., “Apoptotic rate: A new indicator for the quantification of the incidence of apoptosis in cell cultures,” Cytometry. 48(4):185-93 (2002). [cited by applicant]
Qin et al., “Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice,” J Immunol. 150(5):2072-80 (1993). [cited by applicant]
Raab et al., “In vitro evaluation of methotrexate and azathioprine for antipsoriatic activity,” Arch Derm Res. 253(1):77-84 (1975). [cited by applicant]
Rabinovitch et al., “Tumor necrosis factor mediates the protective effect of Freund's adjuvant against autoimmune diabetes in BB rats,” J Autoimmun. 8(3):357-366 (1995). [cited by applicant]
Rajagopalan et al., “Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: Isolation of CD4-8- T helper cell lines that express the γδ T-cell antigen receptor,” Proc Na… [cited by applicant]
Ramiya et al., “Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells,” Nat Med. 6(3):278-282 (2000). [cited by applicant]
Rechsteiner, “Ubiquitin-mediated pathways for intracellular proteolysis,” Annu Rev Cell Biol. 3:1-30 (1987) (16 pages). [cited by applicant]
Rietze et al., “Purification of a pluripotent neural stem cell from the adult mouse brain,” Nature. 412(6848):736-739 (2001). [cited by applicant]
Roberts et al., “Hox11 controls the genesis of the spleen,” Nature. 368:747-749 (1994). [cited by applicant]
Rolfe et al., “The ubiquitin-mediated proteolytic pathway as a therapeutic area,” J Mol Med. 75:5-17 (1997). [cited by applicant]
Rosenthal, “Prometheus's vulture and the stem-cell promise,” N Engl J Med. 349(3):267-74 (2003). [cited by applicant]
Ryu et al., “Reversal of established autoimmune diabetes by restoration of endogenous β cell function,” J Clin Invest. 108(1):63-72 (2001). [cited by applicant]
Satoh et al., “Inhibition of type I diabetes in BB rats with recombinant human tumor necrosis factor-α [cited by applicant]
Schmidt et al., “Interspecies exchange of β [cited by applicant]
Serrano et al., “Non-HLA associations with autoimmune diseases,” Autoimmun Rev. 5(3):209-214 (2006). [cited by applicant]
Serup, “Panning for pancreatic stem cells,” Nat Genet. 25(2):134-135 (2000). [cited by applicant]
Serup et al., “Islet and stem cell transplantation for treating diabetes,” BMJ. 322 (7277):29-32 (2001). [cited by applicant]
Shehadeh et al., “Effect of adjuvant therapy on development of diabetes in mouse and man,” Lancet. 343(8899):706-707 (1994). [cited by applicant]
Shihabuddin et al., “Adult spinal cord stem cells generate neurons after transplantation in the adult dentate gyrus,” J Neurosci. 20(23):8727-8735 (2000). [cited by applicant]
Silva et al., “Prevention of autoimmune diabetes through immunostimulation with Q fever complement-fixing antigen,” Ann NY Acad Sci. 1005:423-430 (2003). [cited by applicant]
Song et al., “Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression,” J Exp Med. 191(7):1095-1103 (2000). [cited by applicant]
Speiser et al., “Loss of ATP-dependent proteolysis with maturation of reticulocytes and erythrocytes,” J Biol Chem. 257(23):14122-14127 (1982). [cited by applicant]
Sreenan et al., “Increased β-Cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse,” Diabetes. 48(5):989-996 (1999). [cited by applicant]
Sun et al., “MHC class I multimers,” Arthritis Res. 3(5):265-269 (2001). [cited by applicant]
Szodoray et al., “Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry,” Lab Invest. 83(12):1839-1848 (2003). [cited by applicant]
Tartaglia et al., “The two different receptors for tumor necrosis factor mediate distinct cellular responses,” Proc Natl Acad Sci USA. 88(20):9292-9296 (1991). [cited by applicant]
Terada et al., “Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion,” Nature. 416(6880):542-545 (2002). [cited by applicant]
Trowsdale et al., “Sequences encoded in the class II region of the MHC related to the ‘ABC’ superfamily of transporters,” Nature. 348(6303):741-4 (1990). [cited by applicant]
Van der Kooy et al., “Why stem cells?,” Science. 287:1439-1441 (2000). [cited by applicant]
Van Nocker et al., “The multiubiquitin-chain-binding protein Mcb1 is a component of the 26S proteasome in [cited by applicant]
Van Noort et al., “Cell biology of autoimmune diseases,” Int Rev Cytol. 178:127-206 (1998). [cited by applicant]
Vidal-Puig et al., “Tolerance to peripheral tissue is transient and maintained by tissue-specific class I expression,” Transplant Proc. 26(6):3314-6 (1994). [cited by applicant]
Vogel, “Stem cell research. Studies cast doubt on plasticity of adult cells,” Science. 295:1989,1991 (2002). [cited by applicant]
Von Herrath et al., “In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes,” J Immunol. 161:5087-5096 (1998). [cited by applicant]
Wang et al., “Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy,” Diabetes. 41:114-117 (1992). [cited by applicant]
Watt et al., “Out of Eden: stem cells and their niches,” Science. 287:1427-30 (2000). [cited by applicant]
Waxman et al., “Demonstration of two distinct high molecular weight proteases in rabbit reticulocytes, one of which degrades ubiquitin conjugates,” J Biol Chem. 262(6):2451-2457 (1987). [cited by applicant]
Weissman, “Translating stem and progenitor cell biology to the clinic: barriers and opportunities,” Science. 287:1442-1446 (2000). [cited by applicant]
Weringer et al., “Identification of T cell subsets and Class I and Class II antigen expression in islet grafts and pancreatic islets of diabetic BioBreeding/Worcester rats,” Am J Pathol. 132(2):292-303 (1988). [cited by applicant]
Wicker et al., “Transfer of autoimmune diabetes mellitus with splenocytes from nonobese diabetic (NOD) mice,” Diabetes. 35:855-860 (1986). [cited by applicant]
Willis et al., “Type 1 Diabetes in insulin-treated adult-onset diabetic subjects,” Diabetes Res Clin Pract. 42:49-53 (1998). [cited by applicant]
Winston, “Embryonic stem cell research: the case for . . . ,” Nat Med. 7(4):396-397 (2001). [cited by applicant]
Wong et al., “Identification of an MHC class I-restricted autoantigen in Type I Diabetes by screening an organ-specific cDNA library,” Nat Med. 5(9):1026-1031 (1999). [cited by applicant]
Xu et al., “MHC/peptide tetramer-based studies of T cell function,” J Immunol Methods. 268(1):21-28 (2002). [cited by applicant]
Yan et al., “Reduced expression of Tap1 and Lmp2 antigen-processing genes in the nonobese diabetic (NOD) mouse due to a mutation in their shared bidirectional promoter,” J Immunol. 159(6):3068-3080 (1997). [cited by applicant]
Ying et al., “Changing potency by spontaneous fusion,” Nature. 416(6880):545-548 (2002). [cited by applicant]
Zöller et al., “Apoptosis resistance in peripheral blood lymphocytes of alopecia areata patients,” Retrieved from Science Direct, published in: J Autoimmun. 23(3):241-256 (2004) (30 pages). [cited by applicant]
Schuppan, “Current concepts of celiac disease pathogenesis,” Gastroenterology. 119(1):234-242 (2000). [cited by applicant]
Beers et al., Disorders of Carbohydrate Metabolism: Diabetes Mellitus. [cited by applicant]
Gupta, “Molecular steps of tumor necrosis factor receptor-mediated apoptosis,” Curr Mol Med. 1(3):317-324 (2001). [cited by applicant]
Hymowitz et al., “Toward small-molecule agonists of TNF receptors,” Nat Chem Biol. 1(7):353-354 (2005). [cited by applicant]
Rath et al., “TNF-induced signaling in apoptosis,” J Clin Immunol. 19(6):350-364 (1999). [cited by applicant]
Kodama et al., “The therapeutic potential of tumor necrosis factor for autoimmune disease: A mechanistically based hypothesis,” Cell Mol Life Sci. 62:1850-1862 (2005). [cited by applicant]
Aranda et al., “Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RB [cited by applicant]
Genestier et al., “Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T Cells,” J Clin Invest. 102(2):322-328 (1998). [cited by applicant]
Gerich et al., “Advances in diabetes for the millennium: Understanding insulin resistance,” MedGenMed. 6(3 Suppl.):11 (2004) (9 pages). [cited by applicant]
Gottlieb et al., “Cell acidification in apoptosis: Granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H [cited by applicant]
Anderson et al., “Studies on the cytophilic properties of human beta2 microglobulin,” J Immunol. 114(3):997-1000 (1975). [cited by applicant]
Ashton-Rickardt et al., “Evidence for a differential avidity model of T cell selection in the thymus,” Cell. 76(4):651-63 (1994). [cited by applicant]
Atkinson et al., “The NOD mouse model of type 1 diabetes: As good as it gets?,” Nat Med. 5(6):601-4 (1999). [cited by applicant]
Baxter et al., “Mycobacteria precipitate an SLE-like syndrome in diabetes-prone NOD mice,” Immunology. 83(2):227-231 (1994). [cited by applicant]
Bjornson et al., “Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo,” Science. 283(5401):534-537 (1999). [cited by applicant]
Brayer et al., “Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjögren's syndrome-like autoimmune exocrinopathy,” J. Rheumatol. 27(8):1896-1904 (2000). [cited by applicant]
Couzin, “Diabetes studies conflict on power of spleen cells,” Science. 311:1694 (2006). [cited by applicant]
Dieguez-Acuna et al., “Characterization of mouse spleen cells by subtractive proteomics,” Mol Cell Proteomics. 4(10):1459-1470 (2005). [cited by applicant]
Feldman et al., “Anti-TNFalpha therapy is useful in rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other diseases,” Transplant Proc. 30(8):4126-4127 (1998). [cited by applicant]
Fu et al., “Antigen processing and autoimmunity: Evaluation of mRNA abundance and function of HLA-Linked genes,” Ann NY Acad Sci. 842:138-155 (1998). [cited by applicant]
Fu et al., “Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity,” J Clin Invest. 91:2301-2307 (1993). [cited by applicant]
Glas et al., “The CD8 [cited by applicant]
Hao et al., “Effect of mycophenolate mofetil on islet allografting to chemically induced or spontaneously diabetic animals,” Transplant Proc. 24(6): 2843-2844 (1992). [cited by applicant]
Kodama et al., “Regenerative medicine: A radical reappraisal of the spleen,” Trends Mol Med. 11(6):271-276 (2005). [cited by applicant]
Sears et al., “NF-kappaB p105 processing via the ubiquitin-proteasome pathway,” J Biol Chem. 273(3):1409-1419 (1998). [cited by applicant]
Shohami et al., “Dual role of tumor necrosis factor alpha in brain injury,” Cytokine Growth Factor Rev. 10(2):119-130 (1999). [cited by applicant]
Slack, “Stem cells in epithelial tissues,” Science. 287:1431-1433 (2000). [cited by applicant]
Storms et al., “Hoechst dye efflux reveals a novel CD7 [cited by applicant]
International Search Report for International Application No. PCT/US2004/037998, mailed Feb. 28, 2008 (2 pages). [cited by applicant]
Written Opinion for International Application No. PCT/US2004/037998, mailed Feb. 28, 2008 (3 pages). [cited by applicant]
Marriott, “TNF-alpha antagonists: Monoclonal antibodies, soluble receptors, thalidomide and other novel approaches,” Expert Opin Invest Drugs. 6(8):1105-1108 (1997). [cited by applicant]
Ferrando et al., “Adult T-Cell ALL patients whose lymphoblasts express the HOX11 oncogene have an excellent prognosis when treated with chemotherapy and are not candidates for allogeneic bone marrow transplantation in f… [cited by applicant]
Al-Awqati et al., “Stem cells in the kidney,” Kidney Int. 61(2):387-95 (2002). [cited by applicant]
Baik et al., “BCG vaccine prevents insulitis in low dose streptozotocin-induced diabetic mice,” Diabetes Res Clin Pract. 46(2):91-97 (1999). [cited by applicant]
Ban et al., “Selective death of autoreactive T Cells in human diabetes by TNF or TNF receptor 2 agonism,” Proc Natl Acad Sci USA. 105(36):13644-13649 (2008). [cited by applicant]
Brodbeck et al., “Genetic determination of nephrogenesis: the Pax/Eya/Six gene network,” Pediatr Nephrol. 19(3):249-255 (2004) (1 page) (Abstract Only). [cited by applicant]
Cavallo et al., “BCG vaccine with and without nicotinamide in recent onset IDDM: a multicenter randomized trial,” Second Congress of the Immunology of Diabetes Society, Canberra, Australia, Dec. 8-11, 1996. Autoimmunity… [cited by applicant]
Choi et al., “Prevention of encephalomyocarditis virus-induced diabetes by live recombinant [cited by applicant]
Cole et al., “Two ParaHox genes, SpLox and SpCdx, interact to partition the posterior endoderm in the formation of a functional gut,” Development. 136(4):541-549 (2009). [cited by applicant]
Dear et al., “The Hox11 gene is essential for cell survival during spleen development,” Development. 121(9):2909-2915 (1995). [cited by applicant]
Declaration of Dr. Denise Faustman under 37 C.F.R. § 1.132 regarding U.S. Appl. No. 10/358,664, dated May 13, 2009 (4 pages). [cited by applicant]
Durand et al., “Mesenchymal lineage potentials of aorta-gonad-mesonephros stromal clones,” Haematologica. 91(9):1172-1179 (2006). [cited by applicant]
Gazda et al., “Regulation of autoimmune diabetes: characteristics of non-islet-antigen specific therapies,” Immunol Cell Biol. 74: 401-407 (1996). [cited by applicant]
Harada et al., “Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination,” Diabetes Res Clin Pract. 8:85-89 (1990). [cited by applicant]
Horsfall et al., “Characterization and specificity of B-cell responses in lupus induced by [cited by applicant]
Horwitz et al., “Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the [cited by applicant]
Hostikka et al., “The mouse Hoxc11 gene: genomic structure and expression pattern,” Mech Dev. 70(1-2):133-145 (1998) (1 page) (Abstract Only). [cited by applicant]
Humphreys-Beher et al., “New concepts for the development of autoimmune exocrinopathy derived from studies with the NOD mouse model,” Arch Oral Biol. 44(Suppl 1):S21-S25 (1999) (Abstract Only) (2 pages). [cited by applicant]
Klingensmith et al., “Vaccination with BCG at diagnosis does not alter the course of IDDM,” Diabetes 57th Annual Meeting and Scientific Sessions, Jun. 21-24, Boston MA. 46(Suppl 1):193A, 0744 (1997) (3 pages) (Abstract … [cited by applicant]
Kouskoff et al., “Organ-specific disease provoked by systemic autoimmunity,” Cell. 87(5):811-22 (1996) (1 page) (Abstract only). [cited by applicant]
Koyama et al., “Hox11 genes establish synovial joint organization and phylogenetic characteristics in developing mouse zeugopod skeletal elements,” Development. 137(22): 3795-800 (2010) (Abstract Only). [cited by applicant]
Murthi et al., “Novel homeobox genes are differentially expressed in placental microvascular endothelial cells compared with macrovascular cells,” Placenta. 29(7):624-630 (2008) (1 page) (Abstract only). [cited by applicant]
Paolillo et al., “The effect of Bacille Calmette-Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS,” J Neurol. 250:247-248 (2003). [cited by applicant]
Qin et al., “BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide,” J Autoimmun. 10:271-278 (1997). [cited by applicant]
Quintana et al., “Experimental autoimmune myasthenia gravis in naïve non-obese diabetic (NOD/LtJ) mice: Susceptibility associated with natural IgG antibodies to the acetylcholine receptor,” Int Immunol. 15(1):11-16 (200… [cited by applicant]
Raju et al., “Characterization and developmental expression of TIx-1, the murine homolog of HOX11,” Mech Dev. 44(1):51-64 (1993). [cited by applicant]
Ristori et al., “Use of Bacille Calmette-Guérin (BCG) in multiple sclerosis,” Neurology. 53:1588-1589 (1999). [cited by applicant]
Roberts et al., “Developmental expression of Hox11 and specification of splenic cell fate,” Am J Pathol. 146(5):1089-1101 (1995). [cited by applicant]
Robinson et al., “A novel NOD-derived murine model of primary Sjogren's Syndrome,” Arthitis Rheum. 41(1):150-156 (1998). [cited by applicant]
Serreze et al., “Th1 to Th2 cytokine shifts in nonobese diabetic mice: Sometimes an outcome, rather than the cause, of diabetes resistance elicited by immunostimulation,” J Immunol. 166(2):1352-1359 (2001). [cited by applicant]
Shehadeh et al., “Repeated BCG vaccination is more effective than a single dose in preventing diabetes in non-obese diabetic (NOD) mice,” Isr J Med Sci. 33(11):711-715 (1997). [cited by applicant]
Singh et al., “Can progression of IDDM be prevented in newly diagnosed patients by BCG immunotherapy?” Diabetes Metab Rev. 13(4):320-321 (1997). [cited by applicant]
Swirski et al., “Identification of splenic reservoir monocytes and their deployment to inflammatory sites,” available in PMC Jan. 7, 2010, published in final edited form as: Science. 325(5940):612-616 (2009) (12 pages). [cited by applicant]
Tamura et al., “In vivo differentiation of stem cells in the aorta-gonad-mesonephros region of mouse embryo and adult bone marrow,” Exp Hematol. 30(8):957-966 (2002) (Abstract Only) (2 pages). [cited by applicant]
Wellik et al., “Hox11 paralogous genes are essential for metanephric kidney induction,” Genes Dev. 16:1423-1432 (2002). [cited by applicant]
Wellik, “The role of Hox11 paralogous genes in prostate development,” Grant Detail. (2009) (1 page)(Abstract only). [cited by applicant]
Yagi et al., “Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD Mouse. I. Generation of suppressor macrophages in spleen cells of BCG-vaccinated mice,” Cell Immunol. 138(1):130-141 (199… [cited by applicant]
Yagi et al., “Possible mechanism of the preventive effect of BCG against diabetes mellitus in NOD Mouse. II. Suppression of pathogenesis by macrophage transfer from BCG-vaccinated mice,” Cell Immunol. 138:142-149 (1991). [cited by applicant]
Yang et al., “Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD Mice. I. The early development of autoimmunity and the diabetogenic process,” J Exp Med. 180(3):995-1004 (1994). [cited by applicant]
Baeuerle et al., “NF-kappaB: Ten years after,” Cell. 87(1):13-20 (1996). [cited by applicant]
Ashton-Rickardt et al., “Peptide contributes to the specificity of positive selection of CD8+ T Cells in the thymus,” Cell. 73(5):1041-9 (1993). [cited by applicant]
Barres, “A new role for glia: generation of neurons!,” Cell. 97(6): 667-70 (1999). [cited by applicant]
Beg et al., “An essential role for NF-kappaB in preventing TNF-alpha-induced cell death,” Science. 274(5288):782-4 (1996). [cited by applicant]
Bendelac et al., “Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4 [cited by applicant]
Bill et al., “Use of soluble MHC class II/peptide multimers to detect antigen-specific T cells in human disease,” Arthritis Res. 4:261-265 (2002). [cited by applicant]
Boches et al., “Role for the adenosine triphosphate-dependent proteolytic pathway in reticulocyte maturation,” Science. 215(4535):978-980 (1982). [cited by applicant]
Brazelton et al., “From marrow to brain: expression of neuronal phenotypes in adult mice,” Science. 290:1775-1779 (2000). [cited by applicant]
Brod et al., “Ingested interferon alpha suppresses Type I diabetes in non-obese diabetic mice,” Diabetologia. 41(10):1227-1232 (1998). [cited by applicant]
Bunting et al., “Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo,” Blood. 96(3):902-909 (2000). [cited by applicant]
Caetano et al., “Effect of methotrexate (MTX) on NAD(P)+ dehydrogenases of HeLa cells: malic enzyme, 2-oxoglutarate and isocitrate dehydrogenases,” Cell Biochem Funct. 15(4):259-264 (1997). [cited by applicant]
Chatenoud et al., “CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice,” J Immunol. 158(6):2947-54 (1997). [cited by applicant]
Colucci et al., “Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide,” J Autoimmunity. 9:271-276 (1996). [cited by applicant]
Corbett et al., “Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans,” Proc Natl Acad Sci USA. 90(5):1731-1735 (1993). [cited by applicant]
Coux et al., “Enzymes catalyzing ubiquitination and proteolytic processing of the p105 precursor of nuclear factor kappaB1,” J Biol Chem. 273(15):8820-8828 (1998). [cited by applicant]
Darzynkiewicz et al., “Use of flow and laser scanning cytometry to study mechanisms regulating cell cycle and controlling cell death,” Clinics in Laboratory Medicine. 21(4):857-873 (2001). [cited by applicant]
Dilts et al., “Autoimmune diabetes: The involvement of benign and malignant autoimmunity,” J Autoimmun. 12:229-232 (1999). [cited by applicant]
Dinarello, “Interleukin-1, Interleukin-1 receptors and Interleukin-1 receptor antagonist,” Intern Rev Immunol. 16:457-499 (1998). [cited by applicant]
Driscoll et al., “The proteasome (multicatalytic protease) is a component of the 1500-kDa proteolytic complex which degrades ubiquitin-conjugated proteins,” J Biol Chem. 265(9):4789-4792 (1990). [cited by applicant]
Eglitis et al., “Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice,” Proc Natl Acad Sci USA. 94:4080-4085 (1997). [cited by applicant]
Elliott et al., “Effect of bacille Calmette-Guérin vaccination on C-peptide secretion in children newly diagnosed with IDDM,” Diabetes Care. 21(10):1691-1693 (1998). [cited by applicant]
Eytan et al., “ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin,” Proc Natl Acad Sci USA. 86:7751-7755 (1989). [cited by applicant]
Fan et al., “Generation of p50 subunit of NF-kappaB by processing of p105 through an ATP-dependent pathway,” Nature. 354:395-398 (1991). [cited by applicant]
Faustman et al., “Abnormal T-lymphocyte subsets in Type I Diabetes,” Diabetes. 38:1462-1468 (1989). [cited by applicant]
Faustman et al., “Linkage of faulty major histocompatibility complex class I to autoimmune diabetes,” Science. 254:1756-1761 (1991). [cited by applicant]
Faustman et al., “Murine pancreatic beta-Cells express H-2K and H-2D but not la antigens,” J Exp Med. 151(6):1563-1568 (1980). [cited by applicant]
Faustman et al., “Prevention of xenograft rejection by masking donor HLA class I antigens,” Science. 252:1700-1702 (1991). [cited by applicant]
Faustman et al., “T-lymphocyte changes linked to autoantibodies. Association of insulin autoantibodies with CD4+CD45R+ lymphocyte subpopulation in prediabetic subjects,” Diabetes. 40(5):590-597 (1991). [cited by applicant]
Fischer et al., “An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity,” J Immunol Methods. 259:159-169 (2002). [cited by applicant]
Foulis, “C.L. Oakley lecture (1987). The pathogenesis of beta cell destruction in Type I (insulin-dependent) diabetes mellitus,” J Pathol. 152(3):141-148 (1987). [cited by applicant]
Fukada et al., “Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis,” Immunity. 5:449-460 (1996). [cited by applicant]
Lahav-Baratz et al., “Reversible phosphorylation controls the activity of cyclosome-associated cyclin-ubiquitin ligase,” Proc Natl Acad Sci USA. 92:9303-9307 (1995). [cited by applicant]
Lakey et al., “BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice,” Transplantation. 57(8):1213-1217 (1994). [cited by applicant]
Li et al., “Abnormal class I assembly and peptide presentation in the nonobese diabetic mouse,” Proc Natl Acad Sci USA. 91(23):11128-11132 (1994). [cited by applicant]
Ljunggren et al., “MHC class I expression and CD8 [cited by applicant]
Fischer et al., “A Tnf receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death,” PloS One. 6(11):e27621 (2011) (11 pages). [cited by applicant]
Loetscher et al., “Human tumor necrosis factor alpha (TNFalpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors,” J Biol Chem. 268(35):26350-26357 (1993). [cited by applicant]
Welborn et al., “A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon,” J Exp Med. 184(1):165-171 (1996). [cited by applicant]
Creasey et al., “Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines,” Cancer Res. 47(1):145-9 (1987). [cited by applicant]
Tavernier et al., “Analysis of the structure-function relationship of tumour necrosis factor. Human/mouse chimeric TNF proteins: general properties and epitope analysis,” J Mol Biol. 211(2):493-501 (1990). [cited by applicant]
Rudinger, “Characteristics of the amino acids as components of a peptide hormone sequence,” in Peptide Hormones, Parsons, ed., University Park Press, Jun. 1976, pp. 1-7. [cited by applicant]
Aldrich et al., “Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice,” Proc Natl Acad Sci USA. 91(14):6525-8 (1994). [cited by applicant]
Alison et al., “Hepatocytes from non-hepatic adult stem cells,” Nature. 406(6793):257 (2000). [cited by applicant]
Anderson et al., “Can stem cells cross lineage boundaries?,” Nat Med. 7(4):393-5 (2001). [cited by applicant]
Aristarkhov et al., “E2-C, a cyclin-selective ubiquitin carrier protein required for the destruction of mitotic cyclins,” Proc Natl Acad Sci USA. 93(9):4294-9 (1996). [cited by applicant]
Baeza et al., “Reg protein: a potential beta-cell-specific growth factor?,” Diabetes Metab. 22(4):229-34 (1996). [cited by applicant]
Baeza et al., “Specific reg II gene overexpression in the non-obese diabetic mouse pancreas during active diabetogenesis,” FEBS Letters. 416(3):364-8 (1997). [cited by applicant]
McKay, “Mammalian deconstruction for stem cell reconstruction,” Nat Med. 6(7):747-748 (2000). [cited by applicant]
Hoffmann et al., “Large-scale in vitro expansion of polyclonal human CD4(+)CD25 [cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US14/15101, mailed Jun. 24, 2014 (14 pages). [cited by applicant]
MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J Mol Biol. 262(5):732-45 (1996) (14 pages). [cited by applicant]
Lamminmäki et al., “Crystal Structure of a Recombinant Anti-Estradiol Fab Fragment in Complex With 17beta -Estradiol,” J Biol Chem. 276(39):36687-94 (2001). [cited by applicant]
EPO Communication Pursuant to Rules 161(2) and 162 EPC for International Application No. PCT/US2014/015101, dated Oct. 15, 2015 (2 pages). [cited by applicant]
Brod et al., “New clinical trial in newly diagnosed type 1 diabetes,” <http://www.diabetesstation.org/articles/brod.htm>, retrieved Jun. 19, 2001 (2 pages). [cited by applicant]
EPO Communication pursuant to Article 94(3) EPC for European Application No. 00914899.0, dated May 25, 2012 (9 pages). [cited by applicant]
EPO Invitation pursuant to Article 94(3) and Rule 71(1) EPC for European Application No. 00914899.0, dated Jun. 2, 2014 (4 pages). [cited by applicant]
EPO Summons to attend oral proceedings pursuant to Rule 115(1) EPC for European Application No. 00914899.0, dated Nov. 12, 2014 (6 pages). [cited by applicant]
EPO Communication pursuant to Article 94(3) and Rule 71(1) EPC for European Application No. 00914899.0, dated Mar. 6, 2015 (3 pages). [cited by applicant]